![EMJ Hematology 9 [Supplement 4] 2021 Front Cover](https://www.emjreviews.com/wp-content/uploads/2021/08/EMJ-Hematology-9-Supplement-4-2021-Front-Cover.jpg)
At the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), held virtually 3rd–5th February 2021, data on the efficacy, safety, pharmacokinetics, and pharmacoeconomics of damoctocog alfa pegol (Jivi®; BAY 94-9027; Bayer, Basel, Switzerland) in severe haemophilia were presented across five posters. Jivi is a site-specifically PEGylated, B-domain deleted recombinant factor VIII, with reduced clearance and extended time in circulation.
Latest articles
All articles
4 Mins
10th
December
EAHAD 2025 Congress Presidential Interview: Flora Peyvandi
I love to do medicine, and I always wanted to do internal medicine-haematology, because I thought haematology was just facing up to blood…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
9 Mins
14th
August
Recent Advancements in wAIHA
AIHA is an acquired, heterogeneous group of rare diseases with a prevalence of 17 per 100,000.1 This group includes wAIHA…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
3 Mins
25th
July
Filgrastim Prophylaxis for Neutropenia in Myelodysplasia Pre-Surgery: Case Report
Myelodysplastic syndromes are a group of disorders that affect the bone marrow, subsequently affecting the growth and relative…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.